Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.83), $0.54 better than the analyst estimate of ($1.37). Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE